Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 18/20 | 0.48 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | RXRG | P48443 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14729682 | 0.87 | RXRA (0.47) | MRGPRX4RXRARXRBRXRGHTR2C | |
| SCHEMBL14729662 | 0.82 | BRD4 (0.43) | RXRARXRBSLC6A4 | |
| SCHEMBL14729703 | 0.80 | MRGPRX4 (0.43) | MRGPRX4RXRARXRBRXRGHTR2C | |
| SCHEMBL14729714 | 0.80 | PTPN1 (0.50) | MRGPRX4RXRARXRBRXRGHTR2C | |
| SCHEMBL14719052 | 0.79 | MRGPRX4 (0.44) | MRGPRX4 | |
| SCHEMBL14729718 | 0.79 | CYP2C19 (0.46) | MRGPRX4RXRARXRBRXRG | |
| SCHEMBL30427926 | 0.78 | MRGPRX4 (0.72) | MRGPRX4 | |
| SCHEMBL14729679 | 0.75 | CYP11B1 (0.44) | MRGPRX4RXRARXRBRXRGHTR2C | |
| SCHEMBL14729678 | 0.75 | PTGER1 (0.46) | MRGPRX4SLC6A4 | |
| SCHEMBL14718544 | 0.75 | HTR2C (0.48) | MRGPRX4RXRARXRBRXRGHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2748149-B1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2015-10-21 | — | — | EP | disclosed |
| WO-2013027000-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | WO | disclosed |
| US-20130052281-A1 | NOVEL COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130052281-A1 | NOVEL COMPOUNDS | ABCG2, F12, UGT1A1 | MRGPRX4 97/4885RXRA 438/4885RXRB 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.